ISM-001
Chronic Stable Angina (Coronary Artery Disease)
Pre-clinicalActive
Key Facts
About IsomAb
IsomAb is a private, preclinical-stage biotech focused on a first-in-class antibody therapy for coronary artery disease, specifically chronic stable angina. The company's scientific foundation, supported by prestigious UK research grants, targets VEGF-A165b to unlock therapeutic angiogenesis and address an unmet need in a large patient population. Led by an experienced management team with strong cardiovascular and biotech venture backgrounds, IsomAb is positioned to advance its lead candidate toward clinical development in a high-value market with limited competition in disease-modifying approaches.
View full company profile